Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Extrawell Pharmaceutical Holdings Limited ( (HK:0858) ) has issued an update.
Extrawell Pharmaceutical Holdings Limited has announced the current composition of its board of directors, led by Chairman Dr. Xie Yi and Chief Executive Officer Dr. Guo Yi, alongside a team of executive and independent non-executive directors. The company also confirmed the membership of its three key board committees—Audit, Remuneration and Nomination—signalling a defined corporate governance structure with independent directors chairing the audit and remuneration functions, which is intended to support oversight, transparency and alignment with best-practice governance standards for stakeholders.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.10 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
More about Extrawell Pharmaceutical Holdings Limited
Extrawell Pharmaceutical Holdings Limited is a Bermuda-incorporated, Hong Kong-listed company operating in the pharmaceutical sector. It focuses on the research, development, manufacturing and sale of pharmaceutical products, serving the healthcare and medical markets in Mainland China and potentially other regions through its listed platform.
Average Trading Volume: 2,394,590
Technical Sentiment Signal: Buy
Current Market Cap: HK$242.2M
For a thorough assessment of 0858 stock, go to TipRanks’ Stock Analysis page.